December 15, 2011 -- Jilin Aodong Medicine has put a hold on its $25 million investment in Vital Therapies, a US medical device maker, pending SFDA approval of Vital Therapies’ Extracorporeal Liver Assist Device (ELAD). In May, Jilin Aodong paid $2 million for a 5% stake in Vital Therapies. The deal included a provision for an additional $25 million investment after six months, contingent on SFDA approval of the ELAD, which hasn’t taken place. More details....
Stock Symbol: (SHE: 000623)
